Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recombinant Human Growth Hormone Injection vs Norditropin in Pediatric GHD
CTR20231290Phase 3Completed
- Sponsor
- Junhemeng Biopharmaceutical
- Start
- May 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of somatropin in growth hormone deficiency (GHD), sponsored by Junhemeng Biopharmaceutical. Started May 2023; status: completed.
02
Drugs
somatropin
03
Conditions
growth hormone deficiency (GHD)
Beyond the preview
Go deeper on CTR20231290.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231290.